Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Cagrilintide represents a novel approach to obesity management
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Triggering global regulatory submissions this year for the treatment of obesity
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
